AR and prostate carcinoma: Through a genome-wide CRISPR-Cas9 screen we identified transducin-like enhancer of split 3 (TLE3) as a modulator of AR inhibitor sensitivity that, upon loss, confers resistance to enzalutamide in prostate cancer cells.